Absorption of a topical steroid and evaluation of adrenal suppression in patients with erosive lichen planus

Plemons, Jacqueline M.; Rees, Terry D.; Zachariah, Ninan

doi:10.1016/0030-4220(90)90349-w

Cited by 57 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Betamethasone valerate pellets (Cawson, 1968) or aerosol (Tyldesley and Harding, 1977) is also effective, as confirmed in a double-blind study of 19 patients (Greenspan et al, 1978). Corticosteroids of this potency, used for several weeks, appear to produce no significant adrenal suppression (Plemons et al, 1990), despite some concern (Beckman, 1981).…”

Section: Corticosteroidsmentioning

confidence: 79%

“…1% in a carboxymethyl cellulose base has been shown to be more effective than a similar triamcinolone acetonide preparation (RoedPetersen and Roed-Petersen, 1992; Thongprasom et al, 1992), though candidosis may complicate this treatment (Thongprasom et al, 1992). Fluocinonide has thus become the first-line treatment for many practitioners involved in the management of OLP (Plemons et al, 1990).…”

Section: Corticosteroidsmentioning

confidence: 99%

See 1 more Smart Citation

Update On Oral Lichen Planus: Etiopathogenesis and Management

Scully

Beyli²,

Ferreiro

et al. 1998

Critical Reviews in Oral Biology & Medicine

476

461

View full text Add to dashboard Cite

Lichen planus (LP) is a relatively common disorder of the stratified squamous epithelia, which is, in many ways, an enigma. This paper is the consensus outcome of a workshop held in Switzerland in 1995, involving a selection of clinicians and scientists with an interest in the condition and its management. The oral (OLP) eruptions usually have a distinct clinical morphology and characteristic distribution, but OLP may also present a confusing array of patterns and forms, and other disorders may clinically simulate OLP. Lesions may affect other mucosae and/or skin. Lichen planus is probably of multifactorial origin, sometimes induced by drugs or dental materials, often idiopathic, and with an immunopathogenesis involving T-cells in particular. The etiopathogenesis appears to be complex, with interactions between and among genetic, environmental, and lifestyle factors, but much has now been clarified about the mechanisms involved, and interesting new associations, such as with liver disease, have emerged. The management of lichen planus is still not totally satisfactory, and there is as yet no definitive treatment, but there have been advances in the control of the condition. There is no curative treatment available; immunomodulation, however, can control the condition. Based on the observed increased risk of malignant development, OLP patients should be offered regular follow-up examination from two to four times annually and asked to report any changes in their lesions and/or symptoms. Follow-up may be particularly important in patients with atrophic/ulcerative/erosive affections of the tongue, the gingiva, or the buccal mucosa. Much more research is required into the genetic and environmental aspects of lichen planus, into the premalignant potential, and into the possible associations with chronic liver, and other, disorders. More clinical studies are required into the possible efficacy of immunomodulatory drugs such as pentoxifylline and thalidomide.

show abstract

Section: Corticosteroidsmentioning

confidence: 79%

Section: Corticosteroidsmentioning

confidence: 99%

Update On Oral Lichen Planus: Etiopathogenesis and Management

Scully

Beyli²,

Ferreiro

et al. 1998

Critical Reviews in Oral Biology & Medicine

476

461

View full text Add to dashboard Cite

show abstract

“…Silverman et aL (1991) reported that all of 22 patients treated with fluocinonide ointment in an Orabase paste achieved approximately 60% improvement in symptoms after 2 weeks. Fluocinonide gel and ointment have proven to be standard, first-line therapies in the treatment of oral lichen planus (Plemons et al, 1990). Lozada-Nur and Huang (1991) studied nine patients with erosive oral lichen planus.…”

Section: A Topicalmentioning

confidence: 99%

The Therapy of Oral Lichen Planus

Eisen

1993

Critical Reviews in Oral Biology & Medicine

View full text Add to dashboard Cite

Oral lichen planus is a chronic mucocutaneous disease that is relatively common. Although many patients are asymptomatic and require no therapy, those who exhibit atrophic and erosive lesions are often a challenge to treat. All therapies are palliative, and none is effective universally. Currently employed treatment modalities include corticosteroids administered topically, intralesionally, or systemically. Alternative therapies include topical and systemic retinoids, griseofulvin, Cyclosporine, and surgery. Other medical treatments and experimental modalities, including mouth PUVA, have been reported to be effective. Controversy concerning the efficacy of all these treatments suggests that oral lichen planus is a heterogeneous disorder. Eliminating lichenoid drug eruptions, candidiasis, trauma, contact mucositis, and emotional stress may play a role in the management of these patients. This article is a review of the many treatments and measures that have been employed in the management of patients with oral lichen planus.

show abstract

“…Thus, this type of treatment should be closely monitored since most of the patients used the corticosteroid up to three weeks. Some reports verified that adrenal suppression might occur as early as 24 h after initiating topical corticotherapy (20,21), even though it is not commonly seen in topical applications. In this study, no side effects were observed with topical use of dexamethasone and one patient presented some kind of allergy to fusidic acid with small ulcerations in lip mucosa in direct contact with the treated area.…”

Section: Discussionmentioning

confidence: 99%

Use of Fusidic Acid for Desquamative Gingivitis Treatment: 1-Year Follow-Up

et al. 2015

View full text Add to dashboard Cite

This study evaluated retrospectively the effect of fusidic acid on the management of desquamative gingivitis (DG). The study population consisted of 15 patients with DG. Patients were requested to make topical application of 2% fusidic acid ointment 4 times a day for 6 weeks. Clinical assessments were recorded at baseline, at 6 weeks and 12 months after beginning the therapy. Patients' examination involved lesion size area, pain score and impact on daily activities. All patients presented lesions in maxilla; in 9 patients (60.0%) lesions were predominately at the anterior region and 6 (40.0%) at the posterior region of maxilla. Treatment significantly (p<0.05) reduced the pain intensity (from 5.4±1.12 to 1.16±0.97) and its periodicity (from 53.33% with pain>3 x/week to 13.33%), and the lesion size in 72.47% (±4.12) immediately after 6 weeks of treatment. Improvements were sustained for 12 months compared to baseline (p<0.001). It also reduced the impact of disease in daily activities (eating and oral hygiene performance), and improved the emotional condition of patients, who reported better social relationships and habits. Topical application of fusidic acid may be a possible alternative local palliative therapy for desquamative gingivitis treatment.

show abstract

Absorption of a topical steroid and evaluation of adrenal suppression in patients with erosive lichen planus

Cited by 57 publications

References 27 publications

Update On Oral Lichen Planus: Etiopathogenesis and Management

Update On Oral Lichen Planus: Etiopathogenesis and Management

The Therapy of Oral Lichen Planus

Use of Fusidic Acid for Desquamative Gingivitis Treatment: 1-Year Follow-Up

Contact Info

Product

Resources

About